“We are continuing to expand our consumer healthcare range through the inclusion of a beauty proposition to address the growing demand,” says Duopharma Biotech GMD
Themed ‘Be Seri-Seri Inside Out’, the launch campaign introduces new ‘best friend’ brand ambassadors and a nationwide Instagram contest with attractive prizes
Kuala Lumpur, 9 April 2021 – This year, in conjunction with World Autism Month, Malaysia’s
largest vitamin brand for children, CHAMPS® – Mother’s Choice for Champions, together with
the charitable non-governmental organisation The National Autism Society of Malaysia
(NASOM), marks their fifth year in collaboration to augment nationwide awareness towards
the acceptance of Autism in Malaysia.
The ISO37001 Anti-Bribery Management System achievement together with the BEIM award is another testament to Duopharma Biotech’s proactive commitment to promulgating a culture of ethics and integrity, says Group MD
Duopharma Biotech is the first Pharmaceutical Company in Malaysia to be awarded the Five Petal Business Ethics Institute of Malaysia (BEIM) Gold Ethics Award’
➢ 4Q PBT leaps to RM20.47 million, a 47% increase over previous corresponding period
➢ EPS climbs to 8.46 sen for the year from previous corresponding year’s 8.25 sen
➢ The Government of Malaysia’s extension of existing Supply Agreements with government
hospitals, clinics stabilises a significant portion of group revenue, placing Duopharma Biotech
in a better position to mobilise resources to intensify foray into specialty and niche products
➢ Supply of Covid-19 vaccine also expected to contribute positively to future earnings
KUALA LUMPUR, 26 JANUARY 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) through its wholly-owned subsidiary Duopharma (M) Sendirian Berhad (“DMSB”) has confirmed it will procure and supply to Malaysia’s Ministry of Health (“MoH”) the COVID-19 vaccine known as “Sputnik V” developed by the Gamaleya National Research Institute of Epidemiology and Microbiology (“Gamaleya”).
Kuala Lumpur, December 18, 2019 – Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma Biotech”) today unveiled its new corporate logo and name at an external rebranding launch. The Company obtained shareholders’ approval for the new corporate identity earlier this year. Duopharma Biotech, which is majority owned by Permodalan Nasional Berhad (PNB), is the largest Malaysian pharmaceutical manufacturer and trading company.
KUALA LUMPUR, 12 NOVEMBER 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a solid set of financial results for the third quarter ended 30 September 2020 with profit before tax holding steady at RM18.57 million (2019: RM19.77 million) against revenue of RM133.77 million (2019: RM142.86 million) despite impact of Covid-19 pandemic.
KUALA LUMPUR, 2 NOVEMBER 2020 – This year’s CHAMPS-NASOM Autism Awareness campaign in Malaysia has advanced to a new level as a result of wider industry collaboration, according to the National Autism Society of Malaysia (“NASOM”) and CHAMPS – Mothers’ Choice for Champions, the established child health supplement brand from the Consumer Healthcare (“CHC”) arm of leading pharmaceutical company Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”).
Shah Alam – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma
Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary,
Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its
first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam,
to help address the paucity of affordable alternatives to treat cancer.
Growing industry collaboration will reinforce CHAMPS-NASOM Autism Awareness Campaign into the future, says Duopharma Biotech Group MD
2020 CHAMPS-NASOM Autism Awareness Campaign, which marks the fourth year of Champs’ support of NASOM’s nation-wide drive to boost public awareness and acceptance of Autism, includes a contribution of RM50,000
Shah Alam, September 15, 2020 – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary, Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam, to help address the paucity of affordable alternatives to treat cancer.
KUALA LUMPUR, 13 AUGUST 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a creditable set of financial results for the second quarter ended 30 June 2020 with profit before tax climbing to RM19.39 million (2019: RM18.32 million) against revenue of RM143.33 million (2019: RM145.47 million).
Kuala Lumpur, 28th July 2020 – Around 500 top industry players gathered online to participate in a webinar held in conjunction with the World Halal Conference (WHC) 2020 webinar series spotlighting the halal pharmaceutical industry.The webinar, entitled ‘Embracing a Halal Pharmaceutical Eco-System’, was organised by the Halal Development Corporation (HDC) in collaboration with Duopharma Biotech Berhad (Duopharma Biotech), and KPJ Healthcare Berhad (KPJ) hosted by the Ministry of International Trade and Industry (MITI).
